A Liver Treatment Starts With the Gut Barrier

Michigan Medicine researchers tested the experimental compound DT-109 in animal models of metabolic dysfunction-associated steatohepatitis. The treatment restored gut-barrier function and reduced the passage of damaging microbial products into circulation, while the animals showed reversal of severe disease markers. The work remains preclinical, but it supports treating MASH as a connected gut-liver system instead of a single-organ problem.